###begin article-title 0
###xml 134 139 <span type="species:ncbi:9606">Human</span>
Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver
###end article-title 0
###begin p 1
###xml 37 62 37 62 <email xmlns:xlink="http://www.w3.org/1999/xlink">anna.kotronen@helsinki.fi</email>
Corresponding author: Anna Kotronen, anna.kotronen@helsinki.fi
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 156 161 <span type="species:ncbi:9606">human</span>
OBJECTIVE-To determine whether 1) hepatic ceramide and diacylglycerol concentrations, 2) SCD1 activity, and 3) hepatic lipogenic index are increased in the human nonalcoholic fatty liver.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
RESEARCH DESIGN AND METHODS-We studied 16 subjects with (n = 8) and without (n = 8) histologically determined nonalcoholic fatty liver (NAFL+ and NAFL-) matched for age, sex, and BMI. Hepatic concentrations of lipids and fatty acids were quantitated using ultra-performance liquid chromatography coupled to mass spectrometry and gas chromatography.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 444 445 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 454 455 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 569 570 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 599 600 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
RESULTS-The absolute (nmol/mg) hepatic concentrations of diacylglycerols but not ceramides were increased in the NAFL+ group compared with the NAFL- group. The livers of the NAFL+ group contained proportionally less long-chain polyunsaturated fatty acids as compared with the NAFL- group. Liver fat percent was positively related to hepatic stearoyl-CoA desaturase 1 (SCD1) activity index (r = 0.70, P = 0.003) and the hepatic lipogenic index (r = 0.54, P = 0.030). Hepatic SCD1 activity index was positively related to the concentrations of diacylglycerols (r = 0.71, P = 0.002) but not ceramides (r = 0.07, NS).
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 90 95 <span type="species:ncbi:9606">human</span>
CONCLUSIONS-We conclude that diacylglycerols but not ceramides are increased in NAFL. The human fatty liver is also characterized by depletion of long polyunsaturated fatty acids in the liver and increases in hepatic SCD1 and lipogenic activities.
###end p 6
###begin p 7
Published ahead of print at  on 24 October 2008.
###end p 7
###begin p 8
M.O. and H.Y.-J. share senior authorship of this study.
###end p 8
###begin p 9
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
###xml 197 198 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 319 320 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 405 406 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 407 408 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 420 421 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 684 685 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 710 711 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 843 844 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 936 937 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 938 939 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1088 1090 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1195 1196 1193 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 536 541 <span type="species:ncbi:9606">human</span>
###xml 1024 1029 <span type="species:ncbi:9606">human</span>
###xml 1277 1282 <span type="species:ncbi:9606">human</span>
Nonalcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver (>/=10% of liver weight), which cannot be attributed to alcohol consumption or any other liver disease (1). NAFLD covers a range from simple nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and fibrosis (1). The fatty liver is resistant to the action of insulin to inhibit hepatic glucose (2,3) and VLDL (4) production, resulting in hyperglycemia and hypertriglyceridemia. The mechanisms underlying insulin resistance in human NAFLD are unclear. While triacylglycerols themselves are inert, lipid intermediates may act as important regulators of both oxidative stress (5) and insulin signaling (6). In vitro studies as well as studies in animals suggest that diacylglycerols, which are immediate precursors of triacylglycerols (7), can induce insulin resistance by activating specific isoforms of protein kinase C (PKC) (8,9). The concentrations of diacylglycerols have recently been shown to be increased in human NAFLD compared with subjects with normal liver histology (10). Ceramides are another class of reactive lipids that mediate saturated fat-induced insulin resistance (6). There are no data comparing ceramide and diacylglycerol concentrations in the human liver or relating them to hepatic fat content.
###end p 10
###begin p 11
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 935 937 935 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 938 940 938 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 776 780 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 941 945 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1109 1114 <span type="species:ncbi:9606">human</span>
Sources of hepatic lipids include dietary chylomicron remnants, free fatty acids released from either adipose tissue triacylglycerols or chylomicrons hydrolyzed at a rate in excess of what can be taken up by tissues (spillover), and de novo lipogenesis (11). Increased lipolysis is a major contributor to hepatic fat accumulation (12-14). In addition, when estimated using tracer techniques, de novo lipogenesis has been found to be significantly increased in subjects with NAFLD compared with normal subjects (12,15,16). De novo lipogenesis produces saturated fatty acids (17,18). Stearoyl-CoA desaturase 1 (SCD1) converts saturated fatty acids to monounsaturated fatty acids, which are major substrates for synthesis of triacylglycerols and other lipids (19). SCD1 knockout mice are resistant to the development of obesity and hepatic steatosis (20,21), whereas the activity of SCD1 is significantly increased in the fatty livers of ob/ob mice (20,22). These data thus suggest that hepatic SCD1 activity may contribute to lipid accumulation in NAFLD. There are, however, no data on hepatic SCD1 activity in human NAFLD.
###end p 11
###begin p 12
###xml 451 452 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 204 209 <span type="species:ncbi:9606">human</span>
To address the above questions, we quantified the full range of lipids and fatty acids using ultra-performance liquid chromatography (UPLC) coupled to mass spectrometry (MS) and gas chromatography in the human liver. These analyses were performed in two groups of subjects matched for age, sex, and BMI but with either a normal liver fat content (</=10% macrovesicular steatosis) or a nonalcoholic fatty liver (NAFL) (>/=20% macrovesicular steatosis [1]).
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 179 180 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 608 616 <span type="species:ncbi:9606">patients</span>
The subjects (all Caucasians and Finns) were recruited from patients undergoing laparoscopic gastric bypass surgery based on the following inclusion criteria: 1) age 18-65 years; 2) no known acute or chronic disease except for obesity or type 2 diabetes based on history, physical examination, and standard laboratory tests (blood counts, serum creatinine, thyroid-stimulating hormone, and electrolyte concentrations), and electrocardiogram; and 3) alcohol consumption <20 g/day. The nature and potential risks of the study were explained to all subjects before obtaining their written informed consent. The patients had not lost weight before surgery (mean weight change over 10 months was -1.1 kg). The study protocol was approved by the ethics committee of the Helsinki University Central Hospital.
###end p 14
###begin p 15
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 886 894 <span type="species:ncbi:9606">patients</span>
###xml 969 977 <span type="species:ncbi:9606">patients</span>
On the morning before surgery, blood samples were taken after an overnight fast for measurement of A1C, fasting serum insulin and C-peptide, liver enzymes, serum triglyceride, and LDL and HDL cholesterol concentrations. Body weight was recorded to the nearest kilogram using a calibrated weighting scale with subjects barefoot and wearing light indoor clothing. Wedge biopsies of the liver were taken at surgery. Approximately one-half of the liver sample was sent to the pathologist for routine histopathological assessment, while the rest was immediately frozen and stored in liquid nitrogen. The fat content of the liver biopsy specimens (percent of hepatocytes with macrovesicular and microvesicular steatosis) was determined by an experienced liver pathologist (J.A.) in a blinded fashion (23). The percent of macrovesicular steatosis was used as the liver fat percent. One of the patients had mild (grade 1) necroinflammatory and fibrotic changes, and two of the patients had mild (grades 1 and 2) fibrotic changes.
###end p 15
###begin title 16
Lipidomic analysis.
###end title 16
###begin p 17
Before analyzing the lipid composition of the liver, frozen samples (5 mg) were mixed with an IS mixture containing 0.5-1 mug/sample of phosphatidylcholine (PC) (17:0/0:0), ceramide (Cer) (d18:1/17:0), PC (17:0/17:0), phosphatidylethanolamine (PE) (17:0/17:0), triglycerides (TGs) (17:0/17:0/17:0), and 200 mul chloroform:methanol (2:1). The tissues were homogenized with grinding balls in a mixer mill at 25 Hz for 2 min, and 50 mul of 0.9% NaCl was added. The samples were vortexed for 2 min, and after 30 min standing, they were centrifuged at 10,000 rpm for 3 min. The labeled lipid standard mixture was added into the separated lipid extracts (1 mug/sample) before UPLC-MS analysis.
###end p 17
###begin p 18
###xml 238 239 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 261 262 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 282 283 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 329 330 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 677 678 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 841 843 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 918 920 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1344 1346 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1565 1566 1557 1558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Lipid extracts were analyzed on a Waters Q-Tof Premier mass spectrometer combined with an Acquity UPLC. The column (at 50degreesC) was an Acquity UPLC bridged ethyl hybrid C18 1 x 50 mm with 1.7-mum particles. The solvent system included 1) water (1% 1 mol/l NH4Ac, 0.1% HCOOH) and 2) acetonitrile/isopropanol (5:2, 1% 1 mol/l NH4Ac, 0.1% HCOOH). The gradient started from 65% A/35% B, reached 100% B in 6 min, and remained there for the next 7 min. There was a 5-min reequilibration step before the next run. The flow rate was 0.200 ml/min, and the injected amount was 1.0 mul. Reserpine was used as the lock spray reference compound. Lipid profiling was carried out using ESI+ mode, and the data were collected at a mass range of 300-1,200 m/z, with a scan duration of 0.2 s. The data were processed by using MZmine software (version 6.0 [24]) and the lipid identification was based on an internal spectral library (25). The relative amounts of all the identified lipids were quantified by calibrating with corresponding class-specific internal standards if available. Sphingomyelins and diacylglycerols were calibrated with PC (17:0/17:0) as an internal standard, while all lysophospholipids were normalized using lysoPC (17:0). Characteristics of the analytical method have been described in detail in the supplement of our previous study (26). The applied platform affords broad screening of multiple lipid classes, including triacylglycerols, cholesterol esters, and major phospholipids, from total lipid extracts within a single sample run. Due to use of ESI+ mode in MS analysis, the platform is not optimal for detection of some negatively charged phospholipids such as phosphatidylserines and phosphatidylinositols. The method does not cover glycosphingolipids or the low-molecular weight reactive lipids such as eicosanoids and free fatty acids.
###end p 18
###begin title 19
Fatty acid analysis.
###end title 19
###begin p 20
Frozen liver tissues (5 mg) were spiked with 40-60 mug standards and homogenized in capped 2-ml microtubes (Sarstedt) at -20degreesC with chloroform:methanol (2:1; 400-600 mul) by using zirconium oxide balls in a mixer mill (25 Hz for 5 min). A total of 100-150 mul NaCl (0.9%) was added by vortexing, and after 1 h extraction time, the lower layer was separated by centrifuging at 10,000 rpm for 5 min. A total of 100-200 mul aliquots from the extracts were evaporated into dryness and used for fatty acid analyses.
###end p 20
###begin p 21
###xml 262 264 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 319 320 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
The evaporation residues were redissolved into 700 mul petroleum ether (boiling point 40-60degreesC) by vortexing. Sodium methoxide (250 mul; 0.5 mol/l NaOMe in MeOH) and a couple of boiling stones were added, and the mixture was boiled at 45degreesC for 5 min (27). The samples were acidified with 500 mul of 15% NaHSO4, 100 mul petroleum ether was added, and the samples were centrifuged in 2 ml microtubes at 10,000 rpm for 5 min. The petroleum ether layers were separated into gas chromatography vials, evaporated, and redissolved into 100 mul hexane.
###end p 21
###begin p 22
Gas chromatographic analysis of fatty acids was performed using the Agilent 5890 series II gas chromatography, equipped with a 25-m FFAP column (0.32 mm inner diameter). The injection volume was 2 mul and split ratio was 1:23. Helium was used as carrier gas and the oven temperature program was from 70degreesC to 240degreesC at 7degreesC/min. The injector and detector (frame ionization detector) temperatures were 260degreesC and 300degreesC, respectively.
###end p 22
###begin title 23
Analytical procedures, measurements, and calculations.
###end title 23
###begin p 24
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
Plasma glucose concentrations were measured in duplicate with the glucose oxidase method using Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, CA) (28). Serum free insulin concentrations were measured with the Auto-DELFIA kit (Wallac, Turku, Finland) and C-peptide concentrations by radioimmunoassay (29). Serum HDL cholesterol and triacylglycerol concentrations were measured with the enzymatic kits from Roche Diagnostics using an autoanalyzer (Roche Diagnostics Hitachi, Hitachi, Tokyo, Japan). The concentration of LDL cholesterol was calculated using the Friedewald formula (30). Serum aspartate transaminase (AST), alanine transaminase (ALT), and gamma glutamyltransferase (gammaGT) activities were determined, as recommended by the European Committee for Clinical Laboratory Standards.
###end p 24
###begin p 25
###xml 211 214 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n &#8722;</italic>
###xml 221 222 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 290 292 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 369 371 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 483 484 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 494 496 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
Desaturase and elongase activities were estimated from product-to-precursor ratios of the percentages of individual fatty acids according to the following equations: SCD1 = (18:1/18:0), Delta6 desaturase = (18:3n - 6/18:2n - 6), Delta5 desaturase = (20:4/20:3), and elongase = (18:0/16:0) (31). Since SCD1 preferentially converts 18:0 to 18:1 rather than 16:0 to 16:1 (19), the 18:1/18:0 index was used to estimate SCD1 activity. The lipogenic index was determined from the 16:0/18:2n-6 ratio (32).
###end p 25
###begin title 26
Statistical analysis.
###end title 26
###begin p 27
###xml 243 244 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 278 279 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 288 289 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 524 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are shown as means +/- SE or, for non-normally distributed data, as median followed by the 25th and 75th percentiles. Correlation analyses were performed using Spearman's nonparametric rank correlation coefficient. The unpaired Student's t test was used to compare the NAFL- and NAFL+ groups. Calculations were made using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA), SysStat Statistical Package (SysStat version 10; SysStat, Evanston, IL), and SPSS 16.0 for Windows (SPSS, Chicago, IL). P < 0.05 was considered statistically significant.
###end p 27
###begin title 28
RESULTS
###end title 28
###begin title 29
Subject characteristics.
###end title 29
###begin p 30
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 355 356 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 373 374 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 382 389 378 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
NAFL+ and NAFL- groups were comparable with respect to age, sex, body weight, BMI, fasting serum insulin, fasting serum C-peptide, A1C, fasting serum triacylglycerols, fasting serum LDL cholesterol, and serum gammaGT concentrations. Fasting serum HDL cholesterol concentrations were lower and serum ALT and serum AST concentrations were higher in the NAFL+ than in the NAFL- group (Table 1).
###end p 30
###begin title 31
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Lipids, fatty acids, and free fatty acids in the NAFL+ versus the NAFL- group.
###end title 31
###begin p 32
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 252 259 252 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 648 649 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 752 753 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 840 847 840 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 903 904 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 941 942 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 965 966 965 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1022 1023 1018 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The concentrations (nmol/mg liver tissue) of glycerophosphatidic acid, ether-linked phosphatidylcholines, lysophosphatidylethanolamine, ether-linked lysophosphatidylethanolamine, and di- and triacylglycerols were higher the NAFL+ than the NAFL- group (Table 2). The concentrations of ceramides, sphingomyelins, phosphatidylcholines, phosphatidylethanolamines, and ether-linked phosphatidylethanolamines were comparable between the groups. The results remained unchanged if the lipid data were normalized to total phospholipid concentrations (data not shown). Total hepatic lipid concentration was positively related to liver fat content (r = 0.53, P = 0.036). The livers of the NAFL+ group contained proportionally more esterified and free oleate (18:1n-9) and less esterified and free stearate (18:0) and long polyunsaturated fatty acids (Table 3) than the NAFL- group. The concentration of oleic (18:1n-9) fatty acid was higher in the NAFL+ group than in the NAFL- group (0.32 +/- 0.04 vs. 0.18 +/- 0.03 nmol/mg tissue, P = 0.007).
###end p 32
###begin title 33
Fatty acid composition of hepatic TGs in relation to liver fat content.
###end title 33
###begin p 34
###xml 302 303 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 325 331 325 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
Correlation coefficients between each of the 136 individual TGs (expressed relative to total hepatic TG) and histological liver fat content were calculated. These correlation coefficients were then plotted against the number of double bonds in the respective TGs. An inverse relationship was observed (r = -0.57, P < 0.0001, Fig. 1), implying that the TGs that were positively associated with liver fat content had only a few double bonds, whereas those TGs negatively related to liver fat content had many double bonds.
###end p 34
###begin title 35
Hepatic desaturase and elongase activities in relation to liver fat content.
###end title 35
###begin p 36
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 156 157 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 172 173 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 263 264 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 273 274 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 284 290 280 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 468 469 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 502 503 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 520 521 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 589 590 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 600 601 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 612 618 596 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 659 660 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 709 710 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 719 720 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 730 736 714 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 784 785 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
The SCD1 activity index, as estimated from the 18:1n-9-to-18:0 fatty acid ratio in the liver was 1.6-fold higher in the NAFL+ (5.7 +/- 0.4) than in the NAFL- (3.7 +/- 0.4, P = 0.004) group. Liver fat percent was positively related to hepatic SCD1 activity index (r = 0.70, P = 0.003, Fig. 2). The activities of Delta5 and Delta6 desaturases in the liver were comparable between the groups (data not shown). The elongase activity index (18:0/16:0) was lower in the NAFL+ (0.23 +/- 0.02) than in the NAFL- (0.33 +/- 0.02, P = 0.005) group and was inversely related to the percent liver fat (r = -0.78, P = 0.0004, Fig. 2). The hepatic lipogenic index (16:0/18:2n-6) was positively related to liver fat content (r = 0.54, P = 0.030, Fig. 2) but unrelated to hepatic SCD1 activity index (r = 0.28, NS).
###end p 36
###begin p 37
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The proportional amounts of long polyunsaturated fatty acids, such as 20:3n-6 and 22:6n-3, were strongly inversely related to SCD1 (r = -0.94, P < 0.0001, and r = -0.82, P < 0.0001) and positively to elongase (r = 0.83, P < 0.0001, and r = 0.86, P < 0.0001) activity indexes in the liver.
###end p 37
###begin title 38
The relationships between hepatic concentrations of diacylglycerols, TGs, ceramides, and SCD1 activity index.
###end title 38
###begin p 39
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 156 162 156 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
The hepatic concentrations of diacylglycerols were positively related to those of TGs (r = 0.58, P = 0.018) and to liver fat percent (r = 0.62, P = 0.0097, Fig. 3). Hepatic SCD1 activity index was positively related to the concentration of diacylglycerols (r = 0.71, P = 0.002) and TGs (r = 0.66, P = 0.005) but unrelated to those of ceramides (r = 0.07, NS) in the liver. The subjects (n = 3) with mild inflammatory or fibrotic changes fell on the same regression lines as others (data not shown).
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin p 41
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
###xml 187 192 <span type="species:ncbi:9606">human</span>
Studies characterizing the human fatty liver are few because of methodological and ethical limitations to sample human liver tissue. In the present study, we analyzed the lipidome of the human liver of subjects with either normal or increased liver fat content due to nonalcoholic causes. We found that hepatic concentrations of diacylglycerols but not ceramides increase with increasing liver fat content. In addition, SCD1 activity index, as estimated from the product-to-precursor ratio, and lipogenic activities were increased, whereas long polyunsaturated fatty acids were depleted in fatty livers.
###end p 41
###begin p 42
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1398 1399 1398 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1400 1401 1400 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 1402 1404 1402 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
###xml 793 797 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 995 999 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1390 1396 <span type="species:ncbi:9606">humans</span>
The final step in triacylglycerol synthesis is catalyzed by diacylglycerol acyltransferases (DGATs), which produce triacylglycerols from diacylglycerols (7). By definition, the concentrations of triacylglycerols in the human fatty liver are increased (1,10,33,34), which may explain the increase in their direct precursors, diacylglycerols (35). Consistent with this, the hepatic concentrations of diacylglycerols were positively related to those of triacylglycerols. In addition, we found hepatic diacylglycerol concentrations to be directly related to liver fat content, as determined by histology. Diacylglycerols are well-known allosteric activators of PKC, an enzyme which has been linked to insulin resistance in a variety of rodent models (36,37) as well as in the human liver (36). In mice, liver-specific overexpression of DGATs results in accumulation of triacylglycerols in the liver, whereas the concentrations of diacylglycerols and the activity of PKC remain unchanged (38). These mice do not exhibit any signs of hepatic insulin resistance (38). On the other hand, suppression of DGAT2 in mice decreases diacylglycerol concentrations and PKC activation and increases hepatic insulin sensitivity (39). These data together with the present findings would imply that diacylglycerols may contribute to hepatic insulin resistance, which is tightly related to liver fat content in humans (2,3,14).
###end p 42
###begin p 43
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 132 134 132 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob</italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 135 139 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 369 375 <span type="species:ncbi:9606">humans</span>
###xml 717 722 <span type="species:ncbi:9606">human</span>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
Ceramides are sphingolipids that appear to mediate saturated fat-induced insulin resistance (6). Lipidomic analyses of livers of ob/ob mice have shown a strong association between hepatic ceramide content and the degree of steatosis (25). The relationships between hepatic ceramide concentrations and inflammatory changes were not analyzed in the latter study (25). In humans, we have previously found adipose tissue to be inflamed and contain more ceramides in subjects with high liver fat content compared with weight-matched subjects with low liver fat content without inflammation in adipose tissue (40). In the present study, we did not find hepatic ceramide concentrations to be related to liver fat content in human livers lacking significant inflammatory and fibrotic changes. These data do not exclude the possibility that ceramides contribute to hepatic insulin resistance in nonalcoholic steatohepatitis. Also, the present negative findings regarding ceramides need to be confirmed in larger groups of patients.
###end p 43
###begin p 44
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 613 617 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 645 651 <span type="species:ncbi:9606">humans</span>
###xml 790 795 <span type="species:ncbi:9606">human</span>
The concentrations of both diacylglycerols and ceramides in myocytes have been shown to increase as a consequence of silencing of SCD1 by siRNA (41). This raises the possibility that metabolism of these bioactive lipids may be regulated by SCD1. In the present study, we found the SCD1 activity index to be positively related to diacylglycerol but not ceramide concentrations. This is consistent with monounsaturated fatty acids, products of SCD1, being necessary for normal rates of synthesis of triacylglycerols (42,43). Hepatic RNA levels and activity of SCD1 are increased in obese (22) and lipoatrophic (44) mice with hepatic steatosis. In humans, SCD1 activity is considerable higher in skeletal muscle of obese compared with lean subjects (45). The present data suggest that, in the human liver, SCD1 activity increases with increasing liver fat content. Direct measurements of SCD1 activity would be helpful in this respect but could not be performed because of limited sample size.
###end p 44
###begin p 45
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 1228 1230 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 1245 1247 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r56">56</xref>
It has recently been shown that short-term high-carbohydrate compared with high-fat feeding activates hepatic SCD1, as estimated from the composition of VLDL-TG fatty acids and de novo lipogenesis in healthy subjects with normal serum ALT concentrations (46). De novo lipogenesis is significantly increased in subjects with NAFLD compared with healthy controls (12,15,16), possibly as a consequence of an increase in sterol regulatory element-binding protein 1c (47-49), a key transcriptional activator of lipogenic genes, including SCD1 (50). In the present study, hepatic lipogenic index, estimated from the 16:0/18:2n-6 ratio (32), was positively related to liver fat content but not to SCD1 activity index. In contrast, the proportional amounts of long polyunsaturated fatty acids in the liver were strongly inversely related to hepatic SCD1 activity index and liver fat content. This is consistent with the ability of polyunsaturated fatty acids to suppress expression of both sterol regulatory element-binding protein 1c (51,52) and SCD1 (53) and activate genes involved in hepatic fatty acid oxidation (31). Subjects with NAFLD have been shown to consume less polyunsaturated fat than normal control subjects in some (54,55) but not all (56) cross-sectional studies.
###end p 45
###begin p 46
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r57">57</xref>
Taken together, these data would suggest that depletion of long polyunsaturated fatty acids derived from essential fatty acids characterizes hepatic fat accumulation. These changes are associated with increases in both the hepatic lipogenic and SCD1 activity indexes. A recent pilot study suggested that prolonged supplementation of n-3 polyunsaturated fatty acids reduces liver fat in subjects with NAFLD (57), suggesting that polyunsaturated fatty acids could be beneficial in treating NAFLD.
###end p 46
###begin p 47
This study was supported by research grants from the Academy of Finland (to H.Y.-J.), the Sigrid Juselius Foundation (to H.Y.-J.), the Finnish Diabetes Research Foundation (to A.K.), and the Biomedicum Helsinki Foundation (to A.K.). This work is part of the project "Hepatic and adipose tissue and functions in the metabolic syndrome" (), which is supported by the European Commission as an Integrated Project under the 6th Framework Programme (contract LSHM-CT-2005-018734) (to H.Y.-J. and M.O.).
###end p 47
###begin p 48
This study also received grant support from Novo Nordisk Foundation (to H.Y.-J.). No other potential conflicts of interest relevant to this article were reported.
###end p 48
###begin p 49
We gratefully acknowledge Mia Urjansson, Katja Tuominen, and Laxman Yetukuri for excellent technical assistance and the volunteers for their help.
###end p 49
###begin title 50
REFERENCES
###end title 50
###begin p 51
###xml 506 507 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 517 518 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Correlation coefficients between each of the 136 individual TG (expressed relative to total hepatic TG) and histological liver fat contents were calculated. These correlation coefficients (Spearman's rho) were then plotted against the number of double bonds in the respective TGs. An inverse relationship was observed, implying that the TGs that were positively associated with liver fat content had only a few double bonds, whereas those TGs negatively related to liver fat content had many double bonds. r = -0.57; P < 0.0001.
###end p 51
###begin p 52
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
The relationships between liver fat content and hepatic SCD1 activity index (A), hepatic elongase activity index (B), and hepatic lipogenic index (C).
###end p 52
###begin p 53
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
The relationships between liver fat content and the hepatic concentrations of diacylglycerols (DG) (A) and ceramides (B).
###end p 53
###begin p 54
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Clinical characteristics of the NAFL- and NAFL+ groups
###end p 54
###begin p 55
Data are means +/- SE or, for non-normally distributed data, medians (25th and 75th percentiles).
###end p 55
###begin p 56
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05,
###end p 56
###begin p 57
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01,
###end p 57
###begin p 58
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.001.
###end p 58
###begin p 59
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Absolute (nmol/mg tissue) lipid concentrations of the livers of the NAFL- and NAFL+ groups
###end p 59
###begin p 60
Data are means +/- SE.
###end p 60
###begin p 61
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01,
###end p 61
###begin p 62
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05. GPA, glycerophosphatidic acid; lysoPE(e), ether-linked lysoPE; lyso(tot), lysoPC and lysoPE; PC(e), ether-linked PC; PE(e), ether-linked PE; SM, sphingomyelin.
###end p 62
###begin p 63
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Proportional hepatic fatty acid composition of the NAFL- and NAFL+ groups
###end p 63
###begin p 64
Data are means +/- SE.
###end p 64
###begin p 65
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01,
###end p 65
###begin p 66
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05,
###end p 66
###begin p 67
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.001.
###end p 67

